Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy
Launched by FRENCH INNOVATIVE LEUKEMIA ORGANISATION · Mar 20, 2025
Trial Information
Current as of May 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying older patients, aged 60 and over, who have been diagnosed with a type of blood cancer called acute myeloid leukemia (AML). The goal is to understand the characteristics of these patients and how they respond to a specific type of treatment known as intensive induction therapy, which aims to achieve complete remission (meaning no signs of cancer). The trial will help researchers learn more about how age and other factors affect treatment outcomes, especially since the incidence of AML increases with age.
To participate in this trial, patients must be 60 years or older, have not received treatment for AML before, and be deemed suitable for intensive therapy. Patients will be asked to read an information document and provide consent for their data to be collected. The study is currently recruiting participants, and while it offers hope for better understanding and treatment of AML in older individuals, it is essential to note that not everyone will be eligible—those with certain health issues or conditions will be excluded. This research is crucial for improving the care and outcomes for older patients with AML.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 60 and over
- • Patients with previously untreated de novo or secondary AML
- • Patients suitable for standard intensive treatment
- • Patients who have read the information document and agreed to the collection of data concerning them (signature of informed consent).
- Exclusion Criteria:
- • Patients with AML 3
- • Patients with severe, uncontrolled infection at the time of inclusion
- • Patients with psychiatric or social disorders that will prevent compliance with the protocol
- • Patients without health insurance (affiliation to a social security scheme)
About French Innovative Leukemia Organisation
The French Innovative Leukemia Organisation (FILO) is a leading clinical trial sponsor dedicated to advancing research and treatment options for leukemia. Committed to enhancing patient outcomes, FILO collaborates with top-tier medical institutions and researchers to facilitate innovative clinical trials that explore new therapies and improve existing treatment protocols. By fostering a multidisciplinary approach, FILO aims to accelerate the development of groundbreaking therapies while prioritizing patient safety and ethical standards in clinical research. Through its initiatives, FILO seeks to transform the landscape of leukemia treatment and contribute to the global fight against this challenging disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Marseille, , France
Saint Priest En Jarez, , France
Angers, , France
Avignon, , France
Bayonne, , France
Besançon, , France
Brest, , France
Grenoble, , France
Metz, , France
Montpellier, , France
Nantes, , France
Nîmes, , France
Pessac, , France
Reims, , France
Rennes, , France
Toulouse, , France
Tours, , France
Vandoeuvre Les Nancy, , France
Strasbourg, , France
Orléans, , France
Mulhouse, , France
Annecy, , France
Colmar, , France
Paris, , France
Perpignan, , France
Poitiers, , France
Patients applied
Trial Officials
Arnaud Pigneux, Prof
Study Chair
French Innovative Leukemia Organization
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported